The first Cytokinetics trade was made in Q2 2019.
Since then Steven Cohen bought shares seventeen more times and sold shares on fifteen occasions. The investor sold all their shares in Q4 2024 and doesn't own any shares in Cytokinetics anymore.
Avg closing price
Price range
Sold 63.4% shares (-294 Thousand shares)
Q4 2024
Avg closing price
$51.89
Price range
$47.04
-
$58.62
Increased shares by 23.8% (+89.2 Thousand shares)
Q3 2024
Avg closing price
$55.74
Price range
$51.22
-
$60.16
Increased shares by 2.8% (+10.1 Thousand shares)
Q2 2024
Avg closing price
$60.36
Price range
$47.86
-
$75.05
Increased shares by 132.2% (+208 Thousand shares)
Q1 2024
Avg closing price
$77.34
Price range
$63.75
-
$108.06
New holding (+157 Thousand shares)
Q4 2023
Avg closing price
$36.21
Price range
$26.88
-
$83.49
Sold -160 Thousand shares
Q3 2023
Avg closing price
$33.30
Price range
$29.46
-
$36.61
New holding (+160 Thousand shares)
Q2 2023
Avg closing price
$37.00
Price range
$32.62
-
$40.75
Sold -272 Thousand shares
Q1 2023
Avg closing price
$40.80
Price range
$33.36
-
$45.71
Increased shares by 748.4% (+240 Thousand shares)
Q4 2022
Avg closing price
$43.03
Price range
$35.77
-
$51.11
Increased shares by 63.0% (+12.4 Thousand shares)
Q3 2022
Avg closing price
$48.13
Price range
$38.54
-
$54.52
Sold 98.8% shares (-1.6 Million shares)
Q2 2022
Avg closing price
$40.26
Price range
$33.93
-
$48.92
Increased shares by 83.3% (+737 Thousand shares)
Q1 2022
Avg closing price
$35.53
Price range
$29.74
-
$46.00
Sold 12.3% shares (-124 Thousand shares)
Q4 2021
Avg closing price
$38.59
Price range
$34.35
-
$46.38
Increased shares by 208.2% (+682 Thousand shares)
Q3 2021
Avg closing price
$29.44
Price range
$18.54
-
$35.74
Sold 12.6% shares (-47.1 Thousand shares)
Q2 2021
Avg closing price
$23.48
Price range
$19.79
-
$26.99
Sold 67.9% shares (-792 Thousand shares)
Q1 2021
Avg closing price
$21.35
Price range
$18.57
-
$25.68
Sold 27.4% shares (-440 Thousand shares)
Q4 2020
Avg closing price
$18.28
Price range
$15.26
-
$28.61
Increased shares by 389.3% (+1.28 Million shares)
Q3 2020